Question-and-Answer Session
Operator
(Operator Instructions). And your first question comes from Corey Cosmo from JPMorgan. Please proceed.
Corey Kasimov - JPMorgan
Good afternoon. Thank you for taking the questions. I want to start with the upcoming Phase II data at ADA and obese diabetics and kind of start framing expectations for that. Clearly I know we shouldn't be expecting anything on par with what we saw in the original Phase II study in otherwise healthy obese patients in terms of 9% placebo-adjusted weight loss and the very low dropout rate, less than 10%, but in this more difficult to treat patient population, what type of numbers would you guys be happy with or trying to benchmark? From a weight loss and a tolerability standpoint or whatever else you could add in terms of color from an A1c reduction standpoint, perhaps depending on what the baseline is for these patients?
Leland Wilson
A very good question, a very tough one to answer. Let me take a piece of it and, Peter, if you would chime in as well. The first thing I think it's well-known in the industry and the medical community that treating Type II diabetics for weight loss is a very difficult challenge. In almost, in all trials that I know of, of weight loss drugs, the percent weight loss is much less in treating diabetic patients than it is in normal obese population. I think that is particularly exacerbated as the disease progresses. The further you get along towards taking two, three diabetic medications and your insulin resistance becomes greater and greater, I think you become more and more resistant to any kind of metabolic change. It is almost to the point where it is too late to cause that. So if you are having patients in trials which have the full gamut of levels of severity or insulin resistance, if you will, then you are going to see quite a wide range.
Now in our 202 studies, we had -- we have patients that range all the way from say mild diabetics all the way to what I would consider to be severe diabetics. So it is reasonable to think that the weight loss will be less in this population than the trial. We have no knowledge of what the weight loss is in this trial at this point, but it is reasonable to consider that it will be less. And so we will just have to wait and see the results. And, Peter, maybe you can give a color to it as well.
- To read the full transcript on Seeking Alpha, click here »
